key: cord-0700794-adr3ack7
authors: Forbes, Nauzer; Hilsden, Robert J.; Martel, Myriam; Ruan, Yibing; Dube, Catherine; Rostom, Alaa; Shorr, Risa; Menard, Charles; Brenner, Darren R.; Barkun, Alan N.; Heitman, Steven J.
title: Association Between Time to Colonoscopy after Positive Fecal Testing and Colorectal Cancer Outcomes: a Systematic Review
date: 2020-10-01
journal: Clin Gastroenterol Hepatol
DOI: 10.1016/j.cgh.2020.09.048
sha: af4b3851c8ba6e561e949c5b04316f0a1024acde
doc_id: 700794
cord_uid: adr3ack7

Background & Aims Colonoscopy is required following a positive fecal screening test for colorectal cancer (CRC). It remains unclear to what extent time to colonoscopy is associated with CRC-related outcomes. We performed a systematic review to elucidate this relationship. Methods An electronic search was performed through April 2020 for studies reporting associations between time from positive fecal testing to colonoscopy and outcomes including CRC incidence (primary outcome), CRC stage at diagnosis, and/or CRC-specific mortality. Our primary objective was to quantify these relationships following positive fecal immunochemical testing (FIT). Two authors independently performed screening, abstraction, and risk of bias assessments. Results From 1,612 initial studies, 8 were included in the systematic review, with 5 reporting outcomes for FIT. Although meta-analysis was not possible, consistent trends between longer time delays and worse outcomes were apparent in all studies. Colonoscopy performed beyond 9 months from positive FIT compared to within 1 month was significantly associated with a higher incidence of CRC, with adjusted odds ratios (AORs) of 1.75 and 1.48 in the two largest studies. These studies also reported significant associations between colonoscopy performed beyond 9 months and higher incidence of advanced stage CRC (stage III or IV) at diagnosis, with AORs of 2.79 and 1.55, respectively. Conclusions Colonoscopy for positive FIT should not be delayed beyond 9 months. Given the additional time required for urgent referrals and surgical planning for CRC, colonoscopy should ideally be performed well in advance of 9 months following a positive FIT.

Colorectal cancer (CRC) is a leading global cause of cancer-related mortality. In 123 2017, there were approximately 1.7 million incident cases and nearly 900,000 deaths 124 attributable to CRC worldwide. 1 Screening for CRC reduces the incidence of and mortality 125 from CRC 2 and is widely recommended in high resource countries. 3 Tests designed to 126 detect occult blood in stool shed by cancers and precursor polyps are widely used for 127 primary screening, including fecal immunochemical tests (FIT) and guaiac-based fecal 128 occult blood tests (FOBT). 4 Five-year survival from CRC is largely determined by stage at 129 diagnosis, ranging from approximately 90% for localized disease to less than 15% once 130 metastatic. 5 Therefore, in cases where these initial screening tests are positive, timely 131 colonoscopy is recommended to rule out the presence of cancer, detect it at an earlier stage 132 and to remove polyps in an effort to ultimately lower the risk of subsequent colorectal 133 neoplasia and death from CRC. 2 134 Adherence to best practice timelines in healthcare can be impacted by a number of 135 patient-, physician-and system-related factors. Limited health care budgets create 136 persistent challenges for all jurisdictions and in particular, single-payer health care 137 systems. On the other end of the spectrum, unique events such as the Coronavirus disease 138 2019 (COVID-19) pandemic can cause major time delays for all non-urgent care due to 139 interruptions in health service supply and/or demand from suitable patients. Health care 140 policy makers, physicians, and patients must understand the implications of delays in care. 141

Furthermore, when health jurisdictions are required to cease or resume usual clinical 142 J o u r n a l P r e -p r o o f practice following a shutdown, it is imperative that access be prioritized based on 143 evidence-based health outcomes. 144

Studies have previously examined the relationship between time to colonoscopy 145 following positive FIT or FOBT and CRC-related outcomes. However, a synthesis of the 146 published literature on this important and timely topic has yet to be performed. As such, 147

we performed a systematic review to assess the association between time interval from 148 positive fecal testing to completion of colonoscopy and CRC outcomes. 149

A systematic review adhering to the Preferred Reporting Items for Systematic 153

Reviews and Meta-Analyses (PRISMA) (Supplementary Materials) was conducted. 6 Our 154 primary objective was to determine whether longer time intervals from a positive FIT to 155 colonoscopy was associated with a higher incidence of CRC, more advanced stage of CRC at 156 diagnosis and/or overall or CRC-specific mortality. In addition, the effect of time from FOBT 157 to colonoscopy and these outcomes was assessed as a secondary study objective. 

We included a study if it met all of the following criteria: (1) it was an observational 175 study (prospective or retrospective) or clinical trial; (2) it included data from patients 176 having received a positive result from either FIT or FOBT; (3) it reported on one or more of 177 the following outcomes of interest: CRC diagnosis at colonoscopy or beyond, stage of CRC at 178 diagnosis, overall or CRC-specific mortality; (4) outcomes data were separated by time 179 from initial fecal test to colonoscopy. A study was excluded if it was a modelling study or a 180 systematic or narrative review. However, the reference sections of such publications were 181 also reviewed to identify potential citations. 182 183

A data abstraction form was created to capture data from each included study, 185

Following the final full-text review stage, two reviewers (NF, SJH) abstracted study data in 186 parallel. Study-specific risk of bias (ROB) assessments according to the Newcastle Ottawa 187 Scale (NOS) 7 were also scored in parallel by two reviewers (NF, MM), with discrepancies 188 resolved by a third reviewer (SJH). 189 190

Our primary outcome was CRC incidence. Secondary outcomes included CRC stage selected for full-text review following the initial title and abstract screen. Two modelling 213 studies were reviewed but excluded. 8, 9 Eight studies were ultimately included in the final 214 systematic review of primary or secondary outcomes, with 5 of these reporting outcomes 215 

Baseline characteristics of studies included in the systematic review for FIT are 222 presented in Table 1 . All included studies were in the form of fully published manuscripts. 223

All five studies were observational. Included studies were published between 2017 and 224 2020. The baseline time comparators for patients to receive colonoscopy following FIT 225 ranged from within 1 to within 3 months, with one study excluding colonoscopies 226 performed within 7 days 13 and another excluding colonoscopies performed within 30 227 days, 14 both in an attempt to eliminate procedures performed in an expedited fashion for 228 heightened suspicion of CRC. Meta-analysis was not performed given the limited numbers 229 of studies that would be comparable within each time cut-off. Summaries of study quality 230 using the NOS are provided in Table 1 , with full assessments provided in the 231 Supplementary Materials. 7 Study quality was moderate to high overall, as per the NOS. 232

The most common sources of potential bias were 1) calculation of CRC incidence during the 233 index colonoscopy only, as opposed to an incidence calculation using a period of months or 234 longer (to account for incomplete or poorly tolerated colonoscopies, or those with poor 235 cleansing), and 2) relatively high rates of patients who did not undergo colonoscopy after 236 positive fecal testing (or with incomplete or absent colonoscopy information), ranging from 237 8% to 38%. These aspects contributed to assessments concluding suboptimal length 238 and/or adequacy of follow-up. 239

Most studies reported CRC detection at the time of colonoscopy, although one study 242 reported cumulative incidence within the 6 month period following colonoscopy. 13 

Baseline CRC incidence (calculated from the earliest possible reference time from positive 244 fecal test to colonoscopy) ranged from 30 to 50 per 1,000 persons. There were significant 245 increases in CRC incidence in patients undergoing colonoscopy at 12 months or later 246 following the initial positive FIT compared to the baseline time cut-off, with incidences 247 ranging from 76 to 98 per 1,000 persons. AORs of CRC incidence associated with 248 comparisons of colonoscopy at ≥ 12 months compared to the baseline time period ranged 249 from 2.17 to 2.25. The two largest observational studies including 123,138 and 70,124 250 patients also found significant associations with colonoscopy at over 9 months compared 251 to within 1 month, with AORs of and 1.75 and 1.48. 13, 15 Though one study reported 252 significantly higher CRC incidence when colonoscopy was performed within 3 months 253 compared to within 1 month (AOR 2.68, 95% CI 2.31 -3.10), 16 two other studies assessing 254 this comparison observed no significant difference. 13, 17 Detailed associations between time 255

to colonoscopy and CRC incidence are presented in Table 2 . An unweighted graphical 256 representation of these associations by study is provided in Figure 2 . 257 258

Advanced stage CRC was defined as Stage III or Stage IV carcinoma as per the 260 American Joint Committee on Cancer Staging Manual. 18 The incidence of advanced stage 261 CRC at index colonoscopy was 4-15 per 1,000 patients when performed within 1 month of 262 a positive fecal test. Though one study found no significant increase in advanced stage CRC 263 when colonoscopy was performed at > 6 months compared to within 1 month, 17 all others 264 found significant associations between time to colonoscopy of 12 or more months and 265 higher incidence of advanced stage CRC, with AORs ranging from 2.11 to 3.22. The two 266 largest included studies also found significant associations between colonoscopy 267 performed at > 9 months versus within 1 month, with AORs of 2.79 and 1.55. 13, 15 Another 268 study found significant associations between colonoscopy within or after 3 months and 269 higher incidence of advanced stage CRC, compared to within 1 month (AORs 1.92 and 270 2.59). 16 Detailed associations between time to colonoscopy and advanced CRC stage are 271 found in Table 2 . An unweighted graphical representation of these associations by study is 272 provided in Figure 3 . Only one study assessed CRC-specific mortality, reporting a 273 significantly worse value with colonoscopy after 12 months (hazard ratio 1.53, 95% 1. In this systematic review, we observed clear associations between longer time delay 289 to colonoscopy after positive fecal-based CRC screening testing and increased incidence of 290 CRC, more advanced cancer stage at diagnosis, and higher CRC-specific mortality. An 291 understanding of these findings is crucial for primary care physicians, endoscopists, 292 administrators of endoscopy units and CRC program planners. While we have qualitatively 293 summarized these important temporal trends, the more challenging task is to translate 294 them into firm recommendations regarding an acceptable delay to colonoscopy following 295 positive fecal testing. been overwhelming around the globe; hence, the measures taken by many countries to 323 protect their health care systems are understandable. At the same time, we must not lose 324 sight of the 'bigger picture', recognizing that many other important diseases continue to 325 affect patients irrespective of the pandemic. Our findings underscoring the importance of 326 time to colonoscopy are especially relevant today, but will remain significant long after the 327 pandemic is over. 328

Although we were unable to pool data from the studies in this systematic review, 329 several important conclusions can be derived from our work. Firstly, time matters; this has 330 been consistently shown across the evidence base that we have summarized. Based on the 331 data from the two largest studies, 13, 15 patients with positive FIT have a higher risk of both 332 incident CRC and advanced CRC when colonoscopy is delayed beyond 9 months from their 333 initial screening test. Though it is intuitive that longer delays to colonoscopy should be 334 associated with worse outcomes, this relatively short timeframe may be surprising from a 335 purely biologic perspective given the established and typically lengthy adenoma to 336 carcinoma sequence. 30 However, considering that FIT positivity predicts the presence of 337 advanced adenoma(s) or CRC in up to 54% and 8% of patients, respectively, 4 it is 338 understandable that the impact of delays is more pronounced in these higher-risk 339 patients. 31 Therefore, in the absence of additional data to guide the field otherwise, time 340 from positive fecal test to colonoscopy should not exceed 9 months. When faced with 341 extenuating circumstances such as a hospital admission for comorbidities, patients can be 342 considered for other forms of full colonic examination such as CT colonography on an 343 invididualized basis. 344

While a 9-month timeframe is supported by evidence, patients diagnosed with CRC 345 at colonoscopy who are suitable for potential curative treatment must also complete 346 additional investigations, be referred for surgery and undergo resection when appropriate, 347 all of which take additional time. 32 In addition, a primary aim of CRC screening is to identify 348 earlier stage cancers and to intervene before the disease advances in stage. Furthermore, 349 associations between time to colonoscopy and worse CRC outcomes were observed far 350 earlier than 9 months in one included study. 16 It is not entirely clear why this more 351 pronounced effect of time was observed in this study, but possibilities could include the 352 influence of a more comorbid or screening-naïve population. 16 Given these considerations, 353

we propose that wherever possible, colonoscopy should not be delayed beyond 6 months 354 of positive fecal testing as an aspirational target (with 9 months as an upper limit). 355

However, in situations where resources remain pressured, future risk prediction models 356 may offer the potential to select those most in need of urgent colonoscopy. Alternatively, 357 adjustments in FIT thresholds could represent another mechanism to ensure timely access 358 to colonoscopy by matching supply and demand. 17 

Our review has several limitations, primarily the result of the study designs and 360 available data presented in the included studies. All of the input studies were 361 observational, and consequently could not account for unmeasured confounders. For 362 instance, one study reported an adjusted odds ratio of CRC of 2.7 when colonoscopy was 363 performed at 3 months compared to within 1 month. 16 Given the dubious biological 364 relationship implicit in this association, this is instead likely representative of important 365 methodological limitations with this input study. Furthermore, only one study adjusted for 366 or excluded patients with signs or symptoms suggestive of CRC. 13 Thus, future studies 367 should aim to adjust for these factors. As an added example, patient-related factors 368 associated with time delays including higher comorbidity 20 we performed a sensitivity analysis comparing the results from studies with less than or 382 greater than 20% non-compliance to follow-up. While this did not yield any additional 383 findings, it should be noted that given the low positive CRC rate at colonoscopy, even a 384 much lower non-adherence rate could result in significant biases in results. Finally, we 385 were ultimately unable to perform a meta-analysis of pooled data as a result of the limited 386 number of studies included in our review and owing to differences in time cut-offs between 387 the studies. Therefore, future research is still needed in this area, and researchers 388 performing this important work should strive to adhere to similar time cut-offs. 389

In conclusion, our study demonstrates clear associations between time from 390 positive fecal screening test to colonoscopy and worse CRC outcomes. Further research is 391 urgently needed to elucidate the optimal timeframe within which those with positive fecal 392 testing should undergo colonoscopy. However, it is clear even now that incident CRC and 393 advanced stage CRC are both higher beyond 9 months. Thus, it is incumbent on practioners 394 and the health system to support completion of colonoscopy well in advance of this time Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.

Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.

12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.

8 Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).

Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I 2 ) for each meta-analysis.

Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).

10, Table 1 , Supp Mat

Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.

Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 9-10, Tables 1 & 2 Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 

24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).

Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).

Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.

27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.

Title Page J o u r n a l P r e -p r o o f

The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study

Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths

Systematic review of colorectal cancer screening guidelines for average-risk adults: Summarizing the current global recommendations

Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer

Cancer statistics

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test

Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study

Time from positive screening fecal occult blood test to colonoscopy and risk of neoplasia

Delayed Colonoscopy Following a Positive Fecal Test Result and Cancer Mortality

Association between time to colonoscopy after a positive guaiac fecal test result and risk of colorectal cancer and advanced stage disease at diagnosis

Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis

Time to Colonoscopy and Risk of Colorectal Cancer in Patients With Positive Results From Fecal Immunochemical Tests

Colonoscopy later than 270 days in a fecal immunochemical test-based population screening program is associated with higher prevalence of colorectal cancer

Time to colonoscopy, cancer probability, and precursor lesions in the Danish colorectal cancer screening program

Association of time to colonoscopy after a positive fecal test result and fecal hemoglobin concentration with risk of advanced colorectal neoplasia

Barriers to full colon evaluation for a positive fecal occult blood test

Socioeconomic variation in uptake of colonoscopy following a positive faecal occult blood test result: a retrospective analysis of the NHS Bowel Cancer Screening Programme

Inappropriate use of the faecal occult blood test in a university hospital in the Netherlands

Appropriateness of endoscopic surveillance recommendations in organised colorectal cancer screening programmes based on the faecal immunochemical test

Evaluation of a VHA collaborative to improve follow-up after a positive colorectal cancer screening test

The appropriate use of fecal immunochemical testing

The Need for an Integrated Patient Navigation Pathway to Improve Access to Colonoscopy After Positive Fecal Immunochemical Testing: A Safety-Net Hospital Experience

Changes in Gastroenterology and Endoscopy Practices in Response to the COVID-19 Pandemic: Results from a North American Survey

ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic

COVID-19: Framework for the Resumption of Endoscopic Activities from the Canadian Association of Gastroenterology

COVID-19: Long-term Planning for Procedure-based Specialties During Extended Mitigation and Suppression Strategies

Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database

Lagtimes in diagnosis and treatment of colorectal cancer: determinants and association with cancer stage and survival

Wait times for cancer surgery in the United States: trends and predictors of delays

Ovid MEDLINE(R) ALL <1946 to

Colorectal Neoplasms/bl, di (32474) 2 ((colorectal* or CRC or colon* or bowel* or rectal or rectum or sigmoid or anal or anus) adj2 (cancer or neoplasm* or tumor* or tumour or carcinom* or sarcom* or adenocarcinom* or adeno?carcinom* or adenom* or lesion*) adj3 (screen* or diagnosis)).tw

* or CRC or colon* or bowel* or rectal or rectum or sigmoid or anal or anus) and (cancer or neoplasm* or tumor* or tumour or carcinom* or sarcom* or adenocarcinom* or adeno?carcinom* or adenom* or lesion*) and (screen* or diagnosis)).kf

ece* or f?ecal) adj3 (immunochemic* or blood)).tw

* or f?ecal) and (immunochemic* or blood)).kf. (788)

gFOBT or FOBT or FOB or haemoccult or hemoccult or sensa or heamoccultsensa or hemocare or hema screen or hemascreen or hemacheck or hema check or hemawipe or hema wipe or hemofec or hemofecia or fecatest or fecatwin or coloscreen or seracult or ez?detect or colocare or flexsure or hemmoquant or immocare or hemochaser or bayer detect or hemeselect or immudia or monohaem or insure or hemodia or instant?view or immocare or magstream or guaiac)

Time Factors/ (1198728) 12 (time adj3 (diagnosis or factor* or wait or delay*)).tw. (205915) 13 time.ti,kf

(f?ece* or f?ecal) and (immunochemic* or blood)).kf. (788) 20 (gFOBT or FOBT or FOB or haemoccult or hemoccult or sensa or heamoccultsensa or hemocare or hema screen or hemascreen or hemacheck or hema check or hemawipe or hema wipe or hemofec or hemofecia or fecatest or fecatwin or coloscreen or seracult or ez?detect or colocare or flexsure or hemmoquant or immocare or hemochaser or bayer detect or hemeselect or immudia or monohaem or insure or hemodia or instant?view or immocare or magstream or guaiac

Delays to colonoscopy of 12 months or more after positive FOBT were significantly associated with higher CRC incidence and more advanced stage of diagnosis (compared to performing colonoscopy within 3 months).

Supplementary